



AVVISO DI CONFERENZA

Si comunica che Martedì 16 aprile 2019, alle ore 16:00, nell'Aula A della Facoltà di Farmacia e Medicina (Edificio CU019) dell'Università Sapienza il



Prof. M. Kalesse

*(Institute of Organic Chemistry, Leibniz University Hannover,
Schneiderberg 1B, 30167 Hannover, and Helmholtz Center for
Infection Research, Inhoffenstr 7, 38124 Braunschweig, Germany)*


terrà una conferenza sul tema

"Synthesis and biological characterization of argyrin F, a proteasome inhibitor with improved in vitro and in vivo activities"

La S.V. è invitata ad intervenire.

Il Direttore
Prof. Bruno Botta

In the quest for new targets in anti-tumor therapy the proteasome and its inhibitors have been in the focus of academic and industrial research. In this context, we recently reported on the p27 stabilization effect of argyrin A through selective inhibition of the proteasome.¹ The talk will cover the synthesis of novel argyrines through a route that takes advantage of modern synthetic transformations and thus allows medicinal application by avoiding pharmacologically problematic functional group manipulations such as the incorporation of selenium compounds.²



[1] a) F. Sasse, H. Steinmetz, T. Schupp, F. Petersen, K. Memmert, H. Hofmann, C. Heusser, V. Brinkmann, P. von Matt, G. Höfle, H. Reichenbach, *J. Antibiot.* **2002**, 55, 543-551; b) Compound A21459 isolated by the Zerilli and Serva group exhibits identical chemical shifts and coupling constants compared to argyrin; b) P. Ferrari, K. Vékey, M. Galimberti, G. G. Gallo, E. Selva, L. F. Zerilli, *J. Antibiot.* **1996**, 49, 150-154; c) E. Selva, G. Gastaldo, G. S. Saddler, G. Toppo, P. Ferrari, G. Carniti, B. P. Goldstein, *J. Antibiot.* **1996**, 49, 145-149.

[2] Nickeleit, S. Zender, F. Sasse, R. Geffers, G. Brandes, I. Soerensen, H. Steinmetz, S. Kubicka, T. Carlonagno, D. Menche, I. Guetgemann, J. Buer, A. Gossler, M. P. Manns, M. Kalesse, R. Frank, N. P. Malek, *Cancer Cell* **2008**, 14, 23-35.